{"success":true,"data":{"pressRelease":{"id":"23797","rtpr_id":"nPn6qg5W5a","ticker":"SASY","exchange":"Euronext Paris","all_tickers":["SASY"],"title":"Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1","author":"PR Newswire","published_at":"2026-05-06T16:42:31.899Z","article_body":"Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1\n\nPR Newswire\n\nDURHAM, N.C., May 6, 2026\n\nThe sponsorship helps expand proven Alpha-1 detection strategies, which will\nenable earlier patient identification\n\nDURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit\norganization powered and funded by the Alpha-1 Foundation, today announced\nSanofi as one of its inaugural industry sponsors. This support further\nstrengthens efforts to accelerate routine detection of Alpha-1 Antitrypsin\nDeficiency (Alpha-1), consistent with clinical practice guidelines.\n\n(https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.html)\n\nAlphaDetect is dedicated to identifying everyone at risk for this progressive,\ngenetic condition by elevating awareness, removing barriers, and expanding\nadoption of testing recommendations in clinical practice guidelines, so that\nAlpha-1 detection becomes routine for patients impacted by lung and liver\ndisease. The organization is increasing the availability of Alpha-1 detection\ntools and support at the practice level while partnering with healthcare\nproviders to strategically advance protocols and technologies across\nhealthcare systems.\n\n\"Sanofi is proud to support AlphaDetect's mission, as one of the inaugural\nsponsors, to increase and accelerate Alpha-1 detection,\" said Alaa Hamed,\nGlobal Head of Medical Affairs, Rare Diseases at Sanofi.  \"This effort\nrepresents a meaningful step forward in uncovering those at risk for this\nextremely underdiagnosed rare disease, which can have a devastating impact.\nThis collaboration reflects our commitment to the Alpha-1 community,\nparticularly in driving awareness and recognition. Ensuring that people who\nhave this underlying genetic condition can uncover this diagnosis earlier in\ntheir care journey is fundamental to their chance of better outcomes. We look\nforward to working with AlphaDetect on this important effort.\"\n\n\"Alpha-1 is a progressive, genetic lung and liver condition where delays in\ndetection may have real, irreversible consequences, \" said Julie Murray, CEO\nof AlphaDetect.  \"The ability to scale proven approaches to identifying\nat-risk patients, quickly and systematically, can inform timely decisions for\nthose impacted. The support and commitment from Sanofi are important and\nappreciated as we continue to advance Alpha-1 detection.\"\n\nAlpha-1 remains significantly underdiagnosed, with more than 90% of affected\nindividuals estimated to be unidentified. It is also the leading known genetic\nrisk factor for COPD and is associated with liver disease in both children and\nadults.  Importantly, detection also provides a point of entry into the\nAlpha-1 community, opening the door to the comprehensive information, support,\nand resources needed for the journey ahead.\n\n\"This support builds on Sanofi's commitment to rare disease and the Alpha-1\ncommunity,\" said Scott Santarella, CEO of the Alpha-1 Foundation. \"It also\nrepresents an important step forward in how we approach detection. By\nexpanding these efforts through AlphaDetect, we can identify more individuals\nearlier and deliver on the Alpha-1 Foundation's mission of improving their\nlives.\"\n\nThe latest clinical guidelines recommend testing for Alpha-1 in all\nindividuals with COPD, treatment-resistant asthma, or unexplained liver\ndisease. Yet real-world results fall far short of this. AlphaDetect is\ncommitted to closing the gap. Sanofi's sponsorship and commitment will help\nAlphaDetect scale efforts to enhance provider education, broaden detection\nstrategies, and work across the Alpha-1 community to identify individuals with\nAlpha-1.\n\nAbout AlphaDetect\n\nAlphaDetect, founded in 2025, accelerates detection to uncover everyone\ngenetically at risk for Alpha-1. Located in Durham, NC,\nAlphaDetect will operate as a limited liability company and a non-profit\nsubsidiary of Alpha-1 Foundation, holding tax-exempt status under Section\n501(c)3 of the Internal Revenue Code.\n\nFor more information, visit https://alpha1.org/alphadetect/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682251-1&h=4032960864&u=https%3A%2F%2Falpha1.org%2Falphadetect%2F&a=https%3A%2F%2Falpha1.org%2Falphadetect%2F)\n\nContact:  Cindy Machles\n\ncmachles@alphadetect.org (mailto:cmachles@alphadetect.org)\n\nAbout Sanofi\nSanofi is an R&D driven, AI-powered biopharma company committed to\nimproving people's lives and delivering compelling growth. We apply our deep\nunderstanding of the immune system to invent medicines and vaccines that treat\nand protect millions of people around the world, with an innovative pipeline\nthat could benefit millions more. Our team is guided by one purpose: we chase\nthe miracles of science to improve people's lives; this inspires us to drive\nprogress and deliver positive impact for our people and the communities we\nserve, by addressing the most urgent healthcare, environmental, and societal\nchallenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY\n\nFor more information, visit  www.sanofi.com (http://www.sanofi.com)\n\nContact: Evan Berland\n\nevan.berland@sanofi.com (mailto:evan.berland@sanofi.com)\n\nAbout the Alpha-1 Foundation \n\nThe Alpha-1 Foundation, founded in 1995, is committed to finding a cure for\nAlpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people\naffected by the condition worldwide. A1F has invested over $100 million to\nsupport Alpha-1 research and programs at 130 institutions in North America,\nEurope, the Middle East , and Australia.  \n\nFor more information, visit alpha1.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682251-1&h=1275069228&u=http%3A%2F%2Fwww.alpha1.org%2F&a=alpha1.org)\n \n\nContact: Jeanne Kushner \n\njkushner@alpha1.org (mailto:jkushner@alpha1.org)\n\n(https://mma.prnewswire.com/media/2973907/Sanofi.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-302764446.html\n(https://www.prnewswire.com/news-releases/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-302764446.html)\n\nSOURCE Alpha-1 Foundation\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg\nhttps://mma.prnewswire.com/media/2973907/Sanofi.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6qg5W5a","title":"Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1","author":"PR Newswire","ticker":"SASY","created":"2026-05-06T16:42:31.899Z","tickers":["SASY"],"exchange":"Euronext Paris","article_body":"Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1\n\nPR Newswire\n\nDURHAM, N.C., May 6, 2026\n\nThe sponsorship helps expand proven Alpha-1 detection strategies, which will\nenable earlier patient identification\n\nDURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit\norganization powered and funded by the Alpha-1 Foundation, today announced\nSanofi as one of its inaugural industry sponsors. This support further\nstrengthens efforts to accelerate routine detection of Alpha-1 Antitrypsin\nDeficiency (Alpha-1), consistent with clinical practice guidelines.\n\n(https://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.html)\n\nAlphaDetect is dedicated to identifying everyone at risk for this progressive,\ngenetic condition by elevating awareness, removing barriers, and expanding\nadoption of testing recommendations in clinical practice guidelines, so that\nAlpha-1 detection becomes routine for patients impacted by lung and liver\ndisease. The organization is increasing the availability of Alpha-1 detection\ntools and support at the practice level while partnering with healthcare\nproviders to strategically advance protocols and technologies across\nhealthcare systems.\n\n\"Sanofi is proud to support AlphaDetect's mission, as one of the inaugural\nsponsors, to increase and accelerate Alpha-1 detection,\" said Alaa Hamed,\nGlobal Head of Medical Affairs, Rare Diseases at Sanofi.  \"This effort\nrepresents a meaningful step forward in uncovering those at risk for this\nextremely underdiagnosed rare disease, which can have a devastating impact.\nThis collaboration reflects our commitment to the Alpha-1 community,\nparticularly in driving awareness and recognition. Ensuring that people who\nhave this underlying genetic condition can uncover this diagnosis earlier in\ntheir care journey is fundamental to their chance of better outcomes. We look\nforward to working with AlphaDetect on this important effort.\"\n\n\"Alpha-1 is a progressive, genetic lung and liver condition where delays in\ndetection may have real, irreversible consequences, \" said Julie Murray, CEO\nof AlphaDetect.  \"The ability to scale proven approaches to identifying\nat-risk patients, quickly and systematically, can inform timely decisions for\nthose impacted. The support and commitment from Sanofi are important and\nappreciated as we continue to advance Alpha-1 detection.\"\n\nAlpha-1 remains significantly underdiagnosed, with more than 90% of affected\nindividuals estimated to be unidentified. It is also the leading known genetic\nrisk factor for COPD and is associated with liver disease in both children and\nadults.  Importantly, detection also provides a point of entry into the\nAlpha-1 community, opening the door to the comprehensive information, support,\nand resources needed for the journey ahead.\n\n\"This support builds on Sanofi's commitment to rare disease and the Alpha-1\ncommunity,\" said Scott Santarella, CEO of the Alpha-1 Foundation. \"It also\nrepresents an important step forward in how we approach detection. By\nexpanding these efforts through AlphaDetect, we can identify more individuals\nearlier and deliver on the Alpha-1 Foundation's mission of improving their\nlives.\"\n\nThe latest clinical guidelines recommend testing for Alpha-1 in all\nindividuals with COPD, treatment-resistant asthma, or unexplained liver\ndisease. Yet real-world results fall far short of this. AlphaDetect is\ncommitted to closing the gap. Sanofi's sponsorship and commitment will help\nAlphaDetect scale efforts to enhance provider education, broaden detection\nstrategies, and work across the Alpha-1 community to identify individuals with\nAlpha-1.\n\nAbout AlphaDetect\n\nAlphaDetect, founded in 2025, accelerates detection to uncover everyone\ngenetically at risk for Alpha-1. Located in Durham, NC,\nAlphaDetect will operate as a limited liability company and a non-profit\nsubsidiary of Alpha-1 Foundation, holding tax-exempt status under Section\n501(c)3 of the Internal Revenue Code.\n\nFor more information, visit https://alpha1.org/alphadetect/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682251-1&h=4032960864&u=https%3A%2F%2Falpha1.org%2Falphadetect%2F&a=https%3A%2F%2Falpha1.org%2Falphadetect%2F)\n\nContact:  Cindy Machles\n\ncmachles@alphadetect.org (mailto:cmachles@alphadetect.org)\n\nAbout Sanofi\nSanofi is an R&D driven, AI-powered biopharma company committed to\nimproving people's lives and delivering compelling growth. We apply our deep\nunderstanding of the immune system to invent medicines and vaccines that treat\nand protect millions of people around the world, with an innovative pipeline\nthat could benefit millions more. Our team is guided by one purpose: we chase\nthe miracles of science to improve people's lives; this inspires us to drive\nprogress and deliver positive impact for our people and the communities we\nserve, by addressing the most urgent healthcare, environmental, and societal\nchallenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY\n\nFor more information, visit  www.sanofi.com (http://www.sanofi.com)\n\nContact: Evan Berland\n\nevan.berland@sanofi.com (mailto:evan.berland@sanofi.com)\n\nAbout the Alpha-1 Foundation \n\nThe Alpha-1 Foundation, founded in 1995, is committed to finding a cure for\nAlpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people\naffected by the condition worldwide. A1F has invested over $100 million to\nsupport Alpha-1 research and programs at 130 institutions in North America,\nEurope, the Middle East , and Australia.  \n\nFor more information, visit alpha1.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682251-1&h=1275069228&u=http%3A%2F%2Fwww.alpha1.org%2F&a=alpha1.org)\n \n\nContact: Jeanne Kushner \n\njkushner@alpha1.org (mailto:jkushner@alpha1.org)\n\n(https://mma.prnewswire.com/media/2973907/Sanofi.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-302764446.html\n(https://www.prnewswire.com/news-releases/sanofi-supports-alphadetect-to-accelerate-detection-of-alpha-1-302764446.html)\n\nSOURCE Alpha-1 Foundation\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2973906/AlphaDetect_Trademark_Logo_Logo.jpg\nhttps://mma.prnewswire.com/media/2973907/Sanofi.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-06T16:42:31.939482212Z","server_sent_at_ms":1778085751939},"received_at":"2026-05-06T16:42:31.996Z","source_url":null},"analysis":{"id":"18338","press_release_id":"23797","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"AlphaDetect announced Sanofi as one of its inaugural industry sponsors to accelerate the routine detection of Alpha-1 Antitrypsin Deficiency.\n\nThe collaboration aims to close the gap between clinical guidelines and real-world testing by expanding provider education and detection strategies.\n\nAlpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified; this support seeks to identify at-risk patients earlier.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Sanofi partners with AlphaDetect to boost rare disease detection awareness."},"keyFigures":{},"quotedText":"Sanofi is proud to support AlphaDetect's mission, as one of the inaugural sponsors, to increase and accelerate Alpha-1 detection","namedEntities":{"people":[{"name":"Alaa Hamed","role":"Global Head of Medical Affairs, Rare Diseases at Sanofi"},{"name":"Julie Murray","role":"CEO of AlphaDetect"},{"name":"Scott Santarella","role":"CEO of the Alpha-1 Foundation"}],"products":["AlphaDetect","Alpha-1 Antitrypsin Deficiency testing"],"companies":[{"name":"Sanofi","ticker":"SNY","relationship":"partner"},{"name":"Alpha-1 Foundation","relationship":"parent_organization"}],"dollarAmounts":[{"amount":"$100 million","context":"invested by Alpha-1 Foundation to support research and programs"}]},"materialImpact":{"score":2,"reasoning":"Sanofi joining as an inaugural sponsor validates the non-profit's mission and provides resources to expand detection strategies. However, specific financial terms of the sponsorship were not disclosed, and the event is a strategic support agreement rather than a material commercial transaction."},"tickerRelevance":{"others":[{"ticker":"SNY","relevance":"partner"}],"primary":"SASY"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"strategic_sponsorship","sectorWeight":"rare_disease"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"AlphaDetect announced Sanofi as one of its inaugural industry sponsors to accelerate the routine detection of Alpha-1 Antitrypsin Deficiency.\n\nThe collaboration aims to close the gap between clinical guidelines and real-world testing by expanding provider education and detection strategies.\n\nAlpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified; this support seeks to identify at-risk patients earlier.","key_figures":{},"named_entities":{"people":[{"name":"Alaa Hamed","role":"Global Head of Medical Affairs, Rare Diseases at Sanofi"},{"name":"Julie Murray","role":"CEO of AlphaDetect"},{"name":"Scott Santarella","role":"CEO of the Alpha-1 Foundation"}],"products":["AlphaDetect","Alpha-1 Antitrypsin Deficiency testing"],"companies":[{"name":"Sanofi","ticker":"SNY","relationship":"partner"},{"name":"Alpha-1 Foundation","relationship":"parent_organization"}],"dollarAmounts":[{"amount":"$100 million","context":"invested by Alpha-1 Foundation to support research and programs"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1a3f9f8af9328a99","schema_hash":"sha256:dc6ca59cd3b6e100","created_at":"2026-05-07T04:25:28.892Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small_cap","eventGravity":"strategic_sponsorship","sectorWeight":"rare_disease"}},"durationMs":null,"modelName":"glm-4.7"}}